title: Annual report of the Australian Meningococcal Surveillance Programme, 2007.
abstract: In 2007 there were 242 laboratory-confirmed cases of invasive meningococcal disease analysed by the National Neisseria Network, a nationwide network of reference laboratories. The phenotypes (serogroup, serotype and serosubtype) and antibiotic susceptibility of 127 isolates of Neisseria meningitidis from invasive cases of meningococcal disease were determined and an additional 115 cases were confirmed by non-culture based methods. Nationally, 192 (85%) confirmed cases where a serogroup was determined were infected with serogroup B and 14 (6.2%) with serogroup C meningococci. The total number of confirmed cases was 29 fewer than the 271 cases identified in 2006. The only jurisdiction to record a substantial increase in laboratory confirmed cases was New South Wales and this was in sporadic cases of serogroup B infection. Typical primary and secondary disease peaks were observed in those aged 4 years or less and in adolescents and young adults respectively. Serogroup B cases predominated in all age groups and jurisdictions. The common phenotypes circulating in Australia were B:15:P1.7, B:4:P1.4 and C:2a:P1.5. No evidence of meningococcal capsular 'switching' was detected. About three-quarters of all isolates showed decreased susceptibility to the penicillin group of antibiotics (minimum inhibitory concentration [MIC] 0.06-0.5 mg/L). All isolates remained susceptible to rifampicin. A single serogroup B isolate had decreased susceptibility to ciprofloxacin (MIC 0.06 mg/L). This was the first local isolate of this type since the original report of this phenomenon in Australia in 2000.
authors.affiliation: john_bates@health.qld.gov.au
authors.forename: John
authors.initials: J
authors.lastname: Tapsall
mesh_terms: D000293:Adolescent; D000328:Adult; D017677:Age Distribution; D000368:Aged; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D001315:Australia / Q000453:epidemiology; D002648:Child; D002675:Child, Preschool; D006801:Humans; D007223:Infant; D008589:Meningococcal Infections / Q000188:drug therapy / Q000453:epidemiology* / Q000382:microbiology; D008826:Microbial Sensitivity Tests; D008875:Middle Aged; D038541:Neisseria meningitidis, Serogroup B / Q000145:classification / Q000187:drug effects / Q000302:isolation & purification; D038542:Neisseria meningitidis, Serogroup C / Q000145:classification / Q000187:drug effects / Q000302:isolation & purification; D038582:Neisseria meningitidis, Serogroup W-135 / Q000145:classification / Q000187:drug effects / Q000302:isolation & purification; D038581:Neisseria meningitidis, Serogroup Y / Q000145:classification / Q000187:drug effects / Q000302:isolation & purification; D010641:Phenotype; D012621:Seasons; D018571:Sentinel Surveillance; D012703:Serotyping; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D000900:Anti-Bacterial Agents